Abstract
The idea that recurrent ischemic stroke could be prevented by closing a patent foramen ovale (PFO) was a source of intense controversy between the cardiology and stroke neurology communities since publication of the first PFO closure series in 1992.1 But after 25 years, the publication of 4 large randomized PFO-stroke trials in 2017-20182-5 conclusively demonstrated significant stroke risk reduction in patients treated with PFO closure and antithrombotic therapy compared with those treated with antithrombotic therapy alone.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of the Society for Cardiovascular Angiography & Interventions
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
